SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced the pricing of $650 million aggregate principal amount of 0% convertible senior notes due 2031 (the "2031 Notes") and $650 million aggregate principal amount...
Hence then, the article about halozyme therapeutics inc announces pricing of private offering of 650 million of convertible senior notes due 2031 and 650 million of convertible senior notes due 2032 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 )
Also on site :
- Can New Windows Increase Your Home’s Value Before You Sell? What Appraisers Look For
- I Assumed My Daughter’s Friend Was Busy All Summer. When School Started, We Both Learned the Truth.
- I Waited 36 Years to Tell Brian Austin Green Why I Might Still Be Grounded Because of Him… His Reaction? Worth the Wait!